Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24696611&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Regulatory effect and mechanisms of carbon monoxide-releasing molecule II on hepatic energy metabolism in septic mice Liang F; Cao J; Qin WT; Wang X; Qiu XF; Sun BWWorld J Gastroenterol 2014[Mar]; 20 (12): 3301-11AIM: To investigate the possible mechanisms of exogenous carbon monoxide-releasing molecule II (CORM-2) intervention on hepatic energy metabolism in experimental sepsis. METHODS: Forty-eight C57BL/6 mice were randomly divided into four groups (n = 12): sham group; cecal ligation and puncture (CLP) group; CLP + CORM-2 group and CLP + iCORM-2 (inactive CORM-2) group. Survival rates were determined after 72 h. Twenty-four similarly treated mice (n = 6 in each group) were assayed for post-operative continuous blood glucose in the first 36 h. Thirty-six similarly treated mice (n = 9 in each group) underwent micro-positron emission tomography (PET) scanning after tail vein injection of (18)F-fluorodeoxyglucose (FDG) 24 h after operation. Plasma and liver specimens were collected for assay of liver pathology, alanine transaminase (ALT) and aspartate transaminase (AST) activities. Hepatic glucokinase activity, lactic acid levels and mitochondrial swelling were also determined. RESULTS: Improved survival was observed in CORM-2 treated mice. Both the CLP and CLP + CORM-2 groups had sustained low blood glucose levels within the first post-operative 36 h. (18)F-FDG micro-PET images showed abnormally high levels of hepatic glucose metabolism (standardized uptake value) in the CLP group (2.76 +/- 0.39 vs 0.84 +/- 0.14, P < 0.01), which declined to normal levels after CORM-2 intervention (1.29 +/- 0.32 vs 2.76 +/- 0.39, P < 0.05). glucokinase activity was markedly increased in the CLP group (6.38 +/- 0.56 U/g vs 4.60 +/- 0.21 U/g, P < 0.01), but was normal after CORM-2 intervention (4.74 +/- 0.14 U/g vs 6.38 +/- 0.56 U/g, P < 0.05). CORM-2 suppressed plasma lactic acid levels (4.02 +/- 0.02 mmol/L vs 7.72 +/- 2.37 mmol/L, P < 0.05) and protected hepatic mitochondria in CLP mice. CORM-2 intervention also reduced elevated plasma AST (199.67 +/- 11.08 U/L vs 379.67 +/- 16.34 U/L, P < 0.05) and ALT (63.67 +/- 12.23 U/L vs 112.67 +/- 9.74 U/L, P < 0.05) activities in CLP mice. CONCLUSION: The release of CO molecules by CORM-2 protects mitochondria and maintains a stable level of hepatic glucose metabolism. Thus, CORM-2 improves liver function and survival in septic mice.|*Gene Expression Regulation[MESH]|Alanine Transaminase/metabolism[MESH]|Animals[MESH]|Aspartate Aminotransferases/metabolism[MESH]|Blood Glucose/metabolism[MESH]|Carbon Monoxide/chemistry[MESH]|Cecum/surgery[MESH]|Fluorodeoxyglucose F18/chemistry[MESH]|Liver/*drug effects/metabolism[MESH]|Male[MESH]|Mice[MESH]|Mice, Inbred C57BL[MESH]|Mitochondria/metabolism[MESH]|Organometallic Compounds/*chemistry[MESH]|Positron-Emission Tomography[MESH]|Sepsis/*metabolism[MESH] |